Only the complex N559-glycan in the synaptic vesicle glycoprotein 2C mediates high affinity binding to botulinum neurotoxin serotype A1.
The extraordinary potency of botulinum neurotoxins (BoNTs) is mediated by their high neurospecificity, targeting peripheral cholinergic motoneurons leading to flaccid paralysis and successive respiratory failure. Complex polysialo gangliosides accumulate BoNTs on the plasma membrane and facilitate subsequent binding to synaptic vesicle membrane proteins which results in toxin endocytosis. The luminal domain 4 (LD4) of the three synaptic vesicle glycoprotein 2 (SV2) isoforms A-C mediates uptake of the clinically most relevant serotype BoNT/A1. SV2C-LD4 exhibits the strongest protein-protein interaction and comprises five putative N-glycosylation sites (PNG sites). Here, we expressed human SV2C-LD4 fused to human IgG-Fc in prokaryotic and eukaryotic expression systems to analyse the effect of N-glycosylation of SV2C on the interaction with BoNT/A1. Mass spectrometric analysis of gSV2CLD-Fc demonstrates glycosylation of N534, N559 and N565, the latter two residing at the BoNT/A interface. Mutational analysis demonstrates that only the N559-glycan, but not N565-glycan increases affinity of BoNT/A for human gSV2C-LD4. The N559-glycan was characterised as a complex core-fucosylated type with a heterogeneity ranging up to tetra-antennary structure with bisecting N-acetylglucosamine which can establish extensive interactions with BoNT/A. The mutant gSV2CLD-Fc N559A displayed a 50-fold increased dissociation rate kd resulting in an overall 12-fold decreased binding affinity in surface plasmon resonance (SPR) experiments. The delayed dissociation might provide BoNT/A more time for endocytosis into synaptic vesicles. In conclusion, we show the importance of the complex N559-glycan of SV2C-LD4, adding a third anchor point beside a ganglioside and the SV2C-LD4 peptide, for BoNT/A neuronal cell surface binding and uptake.
Institut für Toxikologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
Stefan
S
Mahrhold
Division for CBRN Defence and Security, Swedish Defence Research Agency, Cementvägen 20, 90182 Umeå, Sweden.
Tomas
T
Bergström
Biological Toxins, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Seestr. 10, 13353 Berlin, Germany.
Daniel
D
Stern
Biological Toxins, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Seestr. 10, 13353 Berlin, Germany.
Brigitte G
BG
Dorner
Division for CBRN Defence and Security, Swedish Defence Research Agency, Cementvägen 20, 90182 Umeå, Sweden.
Crister
C
Åstot
Institut für Toxikologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625 Hannover, Germany rummel.andreas@mh-hannover.de.
Andreas
A
Rummel
D001374:Azacitidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D019274:Botulinum Toxins, Type A / Q000378:metabolism*; D000077209:Decitabine; D006031:Glycosylation; D008562:Membrane Glycoproteins / Q000378:metabolism*; D011485:Protein Binding; D020349:Surface Plasmon Resonance; D013572:Synaptic Vesicles / Q000378:metabolism*
D008562:Membrane Glycoproteins; D000077209:Decitabine; D019274:Botulinum Toxins, Type A; D001374:Azacitidine
HEK cell expression; LC–MS/MS; N-glycan; botulinum neurotoxin A; surface plasmon resonance; synaptic vesicle glycoprotein 2C